Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Serotonin synthesis relies on endogenous 5-hydroxytryptophan (5-HTP), influenced by tryptophan availability and enzyme activity.
• Key enzymes in serotonin synthesis include tryptophan hydroxylase, indoleamine 2,3-dioxygenase, and tryptophan 2,3-dioxygenase (TDO).
• Peripheral conversion of 5-HTP to serotonin, regulated by amino acid decarboxylase and potentially inhibited by PDIs, affects CNS availability.

Purpose of the Study:

• To review preclinical and clinical evidence on 5-hydroxytryptophan (5-HTP) for depression treatment.
• To evaluate the efficacy of 5-HTP in double-blind, placebo-controlled (DB-PC) trials.
• To assess the safety profile of 5-HTP, focusing on eosinophilia myalgia syndrome (EMS) and serotonin syndrome.

Main Methods:

• Systematic review of preclinical studies.
• Analysis of clinical trials, particularly double-blind, placebo-controlled (DB-PC) studies.
• Review of safety data, including adverse events and specific syndromes.

Main Results:

• Preclinical data suggests potential efficacy of 5-HTP in depression models.
• Clinical evidence from DB-PC trials on 5-HTP for depression is evaluated.
• Safety concerns, including eosinophilia myalgia syndrome (EMS) and serotonin syndrome, are discussed.

Conclusions:

• The review synthesizes evidence on 5-HTP's role in serotonin synthesis and its therapeutic potential for depression.
• Efficacy findings from clinical trials are critically examined.
• A comprehensive safety assessment highlights potential risks associated with 5-HTP supplementation.